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Regulated cell death plays an important role in a myriad of processes 15	
including development, host immunity and tissue homeostasis. The best 16	
understood type of regulated cell death is apoptosis. Often apoptosis is 17	
initiated by mitochondrial outer membrane permeabilisation or MOMP. 18	
Widespread MOMP effectively acts as cellular death sentence; usually it leads 19	
to caspase activation and apoptosis however even without caspases, cells die 20	
post-MOMP through a process called caspase-independent cell death or 21	
CICD.  22	
 23	
The success of directly targeting apoptosis to treat cancer is perhaps best 24	
attested by the recent clinical approval of venetoclax, a BCL-2 targeting drug, 25	
to treat drug-refractory chronic lymphocytic leukemia (CLL). Nevertheless, 26	
engaging apoptosis as a means to treat cancer can be sub-optimal since 27	
therapies often fail to completely eradicate tumour cells. Moreover some 28	
studies suggest that apoptosis may have oncogenic effects (1). These 29	
include, apoptosis induced compensatory proliferation, mitogen-induced 30	
cancer stem cell proliferation as well as establishment of an 31	
immunosuppressive microenvironment. Furthermore, sub-lethal engagement 32	
of caspase activity in cells can lead to genomic instability, potentially boosting 33	
tumour evolution (2). Because caspases promote these effects, coupled to 34	
them not being required for MOMP-dependent killing, prompted us to ask 35	
whether CICD might be a better way to kill cancer cells. 36	
 37	
To answer this question, we initially focused on understanding mechanisms 38	
underlying CICD. We found that inhibition of caspases downstream of MOMP 39	
can trigger necroptosis as a form of caspase-independent cell death (CICD), 40	
through the production and autocrine effects of pro-inflammatory TNF (3). 41	
Recent studies underline anti-tumorigenic effects of inducing necroptosis, 42	
however RIPK3 –a protein typically essential for necroptosis execution- is 43	
silenced in the majority of cancers (4). As such, the clinical utility of engaging 44	
necroptosis in cancer treatment remains unclear. 45	
 46	
Nevertheless, we noticed that cells undergoing CICD, independent of 47	
necroptosis, produce several inflammatory cytokines that are important for 48	
recruitment and activation of both innate and adaptive immune responses (3). 49	
In a tumourigenesis experiment setup to mimic partial therapeutic response, 50	
engagement of CICD but not apoptosis led to tumour infiltration of 51	
inflammatory polarised macrophages and activated T-cells (both cytotoxic and 52	
helper) (3). Whereas engagement of apoptosis had no beneficial effect, 53	
triggering CICD in vivo was sufficient to completely eradicate tumours 50% of 54	
the time, dependent on intact immunity. This suggests that triggering CICD in 55	
tumours rather than apoptosis may be a better strategy in cancer treatment. 56	
   57	
Given that mitochondrial apoptosis is typically considered immunologically 58	
silent how can CICD be pro-inflammatory? Addressing this, we found that the 59	
anti-tumourigenic and pro-inflammatory nature of MOMP is dependent on NF-60	
κB - a master transcriptional regulator of pro-inflammatory cytokines (3). 61	
Under caspase deficient conditions, we found that mitochondrial 62	
permeabilisation activates NF-κB in a manner dependent on IAP down-63	
regulation and NIK activation (3). Interestingly, previous studies have shown 64	
that caspase deficiency also allows MOMP to trigger type I IFN response via 65	
the cGAS/STING pathway, activated by mitochondrial DNA (5, 6). We found 66	
that although NF-κB and STING can be activated independently during CICD, 67	
both are required for optimal cytokine production (3). How do caspases 68	
silence inflammation? One possibility might be cleavage dependent 69	
inactivation of molecules important for engaging NF-κB and STING signalling. 70	
Alternatively, it may simply be a difference of kinetics; apoptosis occurs very 71	
rapidly post-MOMP, within minutes, whereas CICD can take many hours to 72	
days, affording the cell time to produce cytokines before death.  73	
 74	
In our view, engaging CICD as an anti-cancer treatment offers two potential 75	
benefits compared with apoptosis: 1) it prevents caspase dependent 76	
oncogenic effects of apoptosis 2) it can activate anti-tumour immunity (Figure 77	
1).  The second point is intriguing, since immunogenicity of death is largely 78	
considered a key feature of uncontrolled necrosis which allows the passive 79	
release of intracellular molecules named DAMPs (damage-associated 80	
molecular patterns) capable of alerting an immune response. Our work 81	
supports recent findings from others whereby dying cells initiate anti-tumour 82	
immunity in a regulated manner dependent on de novo synthesis of 83	
inflammatory signals (3, 7). Therefore, in order to find a more effective way to 84	
kill cancer cells, we might turn our focus on the signals accompany a cell 85	
during its death rather than simply the execution of cell death per se. Going 86	
forward, several key questions remain. How exactly does CICD induce an 87	
immune response? Are there additional mitochondrial pathways that signal 88	
immunity and how do caspases silence these effects? Most importantly, can 89	
we clinically translate these findings, engaging CICD to improve cancer 90	
treatment?  91	
  92	
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Figure 1 Legend 118	
Under conditions of partial therapeutic response, tumour CICD can have two 119	
anti-cancer effects. Engaging MOMP-under caspase inhibited conditions 120	
triggers cell death and anti-tumour immunity dependent upon NFκB in the 121	
dying cell. Anti-tumour immunity can kill remaining tumour cells.  122	
 123	
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